Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;12(5):e1648.
doi: 10.1002/wrna.1648. Epub 2021 Mar 7.

Nanocarrier-delivered small interfering RNA for chemoresistant ovarian cancer therapy

Mingyuan Zou  1 , Yue Du  2 , Ruizhen Liu  3 , Zeliang Zheng  4 , Jian Xu  4
Affiliations
Review

Nanocarrier-delivered small interfering RNA for chemoresistant ovarian cancer therapy

Mingyuan Zou et al. Wiley Interdiscip Rev RNA. 2021 Sep.

Abstract

Ovarian cancer is the fifth leading cause of cancer-related death in women in the United States. Because success in early screening is limited, and most patients with advanced disease develop resistance to multiple treatment modalities, the overall prognosis of ovarian cancer is poor. Despite the revolutionary role of surgery and chemotherapy in curing ovarian cancer, recurrence remains a major challenge in treatment. Thus, improving our understanding of the pathogenesis of ovarian cancer is essential for developing more effective treatments. In this review, we analyze the underlying molecular mechanisms leading to chemotherapy resistance. We discuss the clinical benefits and potential challenges of using nanocarrier-delivered small interfering RNA to treat chemotherapy-resistant ovarian cancer. We aim to elicit collaborative studies on nanocarrier-delivered small interfering RNA to improve the long-term survival rate and quality of life of patients with ovarian cancer. This article is categorized under: RNA Methods > RNA Nanotechnology Regulatory RNAs/RNAi/Riboswitches > RNAi: Mechanisms of Action.

Keywords: chemotherapy resistance; nanocarrier; ovarian cancer; small interfering RNA; targeted therapy.

PubMed Disclaimer

References

REFERENCES

    1. Abrica-Gonzalez, P., Zamora-Justo, J. A., Sotelo-Lopez, A., Vazquez-Martinez, G. R., Balderas-Lopez, J. A., Munoz-Diosdado, A., & Ibanez-Hernandez, M. (2019). Gold nanoparticles with chitosan, N-acylated chitosan, and chitosan oligosaccharide as DNA carriers. Nanoscale Research Letters, 14(1), 258. https://doi.org/10.1186/s11671-019-3083-y
    1. Agarwal, R., & Kaye, S. B. (2003). Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nature Reviews. Cancer, 3(7), 502-516. https://doi.org/10.1038/nrc1123
    1. Ainalem, M. L., Bartles, A., Muck, J., Dias, R. S., Carnerup, A. M., Zink, D., & Nylander, T. (2014). DNA compaction induced by a cationic polymer or surfactant impact gene expression and DNA degradation. PLoS One, 9(3), e92692. https://doi.org/10.1371/journal.pone.0092692
    1. Al-Alem, L. F., Baker, A. T., Pandya, U. M., Eisenhauer, E. L., & Rueda, B. R. (2019). Understanding and targeting apoptotic pathways in ovarian cancer. Cancers (Basel), 11(11), 1631. https://doi.org/10.3390/cancers11111631
    1. Altieri, D. C. (2003). Validating survivin as a cancer therapeutic target. Nature Reviews. Cancer, 3(1), 46-54. https://doi.org/10.1038/nrc968

Substances

LinkOut - more resources